J. Serra - Boehringer Ingelheim Espana SA

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

34P Updated Data from Beamion LUNG-1, a Phase (ph) Ia/b Trial of the HER2-specific Tyrosine Kinase Inhibitor (TKI), Zongertinib (BI 1810631), in Patients (pts) with HER2 Mutation-Positive (m+) NSCLC

Y-L. Wu,F. Opdam,M. Barve,H. Tu,D. Berz, M. Rohrbacher,B. Sadrolhefazi,J. Serra,K. Yoh, N. Yamamoto,J. Heymach

ESMO Open (2024)

引用0浏览0引用

40P Updated Data from the Phase I Beamion Lung 1 Trial of BI 1810631, a HER2 TKI, in Patients (pts) with Advanced Solid Tumours with HER2 Aberrations

F. Opdam,J. Heymach,M. Barve,H-Y. Tu,Y-L. Wu, N. J. Gibson,B. Sadrolhefazi,J. Serra,K. Yoh,N. Yamamoto

Journal of Thoracic Oncology（2023）

引用0浏览0引用

1375P Beamion Lung 1, an Ongoing Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients (pts) with Advanced Solid Tumors with HER2 Aberrations: Latest Data

F. Opdam,J. Heymach,G. Ruiter,M. Barve,H. Tu,Y-L. Wu,L. Schroeter,B. Sadrolhefazi,J. Serra,K. Yoh,N. Yamamoto

Annals of oncology（2023）

引用0浏览0引用

Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations

N. Yamamoto,F. Opdam,M. Barve,H. -Y. Tu,Y. -L. Wu,L. Schroeter,B. Sadrolhefazi,J. Serra,K. Yoh,J. Heymach

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S147-S147

引用0浏览0引用

MA13.08 Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations

N. Yamamoto,F. Opdam,M. Barve,H.-Y. Tu,Y.-L. Wu,L. Schroeter,B. Sadrolhefazi,J. Serra,K. Yoh,J. Heymach

Journal of Thoracic Oncology（2023）

引用0浏览0引用

A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations

F. Opdam,J. Heymach,M. Barve,N. Gibson,B. Sadrolhefazi,J. Serra,N. Yamamoto,K. Yoh,Y. -L. Wu

JOURNAL OF THORACIC ONCOLOGY（2022）

引用0浏览0引用

A Phase I Trial of BI 1810631, a HER2 Tyrosine Kinase Inhibitor (TKI), As Monotherapy in Patients (pts) with Advanced/metastatic Solid Tumors with HER2 Aberrations

F. Opdam,J. Heymach,M. Barve,Y. L. Wu,N. Gibson,B. Sadrolhefazi,J. Serra,K. Yoh,N. Yamamoto

European journal of cancer（2022）

引用2浏览0引用

EP08.02-049 A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, in Patients with Advanced Solid Tumors with HER2 Aberrations

F. Opdam,J. Heymach,M. Barve,N. Gibson,B. Sadrolhefazi,J. Serra,N. Yamamoto,K. Yoh,Y.-L. Wu

Journal of Thoracic Oncologyno. 9 (2022): S421-S422

引用0浏览0引用

Abstract OT3-06-02: A Phase Ib Trial of Xentuzumab and Abemaciclib in Patients with Locally Advanced or Metastatic Solid Tumors, Including Hormone Receptor-Positive, HER2-negative Breast Cancer (plus Endocrine Therapy)

D Yee,MP Sablin, H Iwata,EL Johnston,T Bogenrieder,J Serra, H Hua, P Lo Russo,A Prat

Cancer research（2018）

引用0浏览0引用

A Phase Ib Trial of Xentuzumab and Abemaciclib in Patients with Locally Advanced or Metastatic Solid Tumours, Hormone Receptor-Positive (HR+), HER2-negative (HER2-) Breast Cancer (BC; +/-Endocrine Therapy), or Non-Small-cell Lung Cancer (NSCLC)

A. Prat,D. Yee,M. P. Sablin,H. Iwata,E. L. Johnston,T. Bogenrieder,J. Serra, K. Stucke-Straub,P. Lo Russo

Annals of Oncology（2017）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn